CytomX Income Statement Research
CTMX Stock | USD 2.19 0.08 3.79% |
CytomX |
Most accounts from CytomX Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out CytomX Therapeutics Valuation and CytomX Therapeutics Correlation analysis. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Other Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 86.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 69.6M | 53.2M | 99.0M | 53.9M | Total Revenue | 69.6M | 53.2M | 101.2M | 54.2M |
CytomX Therapeutics income statement Correlations
Click cells to compare fundamentals
CytomX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytomX Therapeutics income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 10.8M | 1.8M | 172K | 2.0M | 2.3M | 2.1M | |
Total Revenue | 57.5M | 100.4M | 69.6M | 53.2M | 101.2M | 54.2M | |
Gross Profit | 57.5M | 100.4M | 69.6M | 53.2M | 99.0M | 53.9M | |
Operating Income | (110.9M) | (48.6M) | (83.8M) | (101.3M) | (6.5M) | (6.8M) | |
Ebit | (110.9M) | (48.6M) | (83.8M) | (101.3M) | (6.5M) | (6.8M) | |
Research Development | 131.6M | 112.9M | 114.2M | 111.6M | 75.7M | 86.4M | |
Ebitda | (108.3M) | (46.0M) | (81.1M) | (98.9M) | (4.3M) | (4.5M) | |
Cost Of Revenue | 105.5M | 0.0 | 5.8M | 5.9M | 2.2M | 2.1M | |
Income Before Tax | (102.7M) | (46.8M) | (83.6M) | (99.3M) | 3.3M | 3.5M | |
Net Income | (102.2M) | (32.9M) | (80.6M) | (97.3M) | (569K) | (597.5K) | |
Income Tax Expense | (427K) | (13.9M) | (3.0M) | (2.0M) | 3.9M | 4.1M | |
Tax Provision | 14.3M | (427K) | (13.9M) | 0.0 | 2.8M | 3.0M | |
Interest Income | 8.4M | 1.8M | 255K | 1.7M | 8.1M | 4.1M | |
Net Interest Income | 8.4M | 1.8M | 255K | 1.7M | 8.1M | 4.3M |
Pair Trading with CytomX Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CytomX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CytomX Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with CytomX Stock
0.67 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
0.61 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against CytomX Stock
0.85 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.81 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
0.61 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.57 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.52 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to CytomX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CytomX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CytomX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CytomX Therapeutics to buy it.
The correlation of CytomX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CytomX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CytomX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CytomX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CytomX Therapeutics Valuation and CytomX Therapeutics Correlation analysis. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for CytomX Stock analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is CytomX Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. If investors know CytomX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytomX Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Revenue Per Share 1.371 | Quarterly Revenue Growth 0.322 | Return On Assets (0.02) | Return On Equity (54.75) |
The market value of CytomX Therapeutics is measured differently than its book value, which is the value of CytomX that is recorded on the company's balance sheet. Investors also form their own opinion of CytomX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytomX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytomX Therapeutics' market value can be influenced by many factors that don't directly affect CytomX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytomX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytomX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.